Jonathan Bendheim - Phibro Animal President
| PAHC Stock | USD 23.73 0.14 0.59% |
President
Mr. Jonathan Bendheim is Director and President, MACIE Region and General Manager of Israel Operations of the Company. He joined Phibro in 2001 as a Manager for logistics and supply chain. In 2005, Mr. Bendheim was appointed Vice President of Sales and Business Development for our Israel operations. In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of our operations in Israel. In 2011, his responsibilities were expanded to include oversight of all sales activities in the MACIE Region. In 2014, Jonathan led the establishment of Phibros global aquaculture business. Mr. Bendheim holds a B.A. degree in political science from Yeshiva University and an MBA from Columbia Business School. Mr. Bendheim is a son of Jack C. Bendheim. Mr. Bendheim is qualified to serve on our Board of Directors due to his extensive management experience in all facets of Phibros animal health and nutrition businesses during his tenure with the Company.
| Age | 48 |
| Address | Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712 |
| Phone | 201 329 7300 |
| Web | https://www.pahc.com |
Phibro Animal Management Efficiency
The company has return on total asset (ROA) of 0.0526 % which means that it generated a profit of $0.0526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0655 %, meaning that it created $0.0655 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to 0. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Phibro Animal's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.66, whereas Total Assets are forecasted to decline to about 568.4 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Daniell | Teva Pharma Industries | 57 | |
| Eliyahu Kalif | Teva Pharma Industries | 50 | |
| Robert Davis | Intracellular Th | 73 | |
| Lisa Paley | Haleon plc | 57 | |
| Mark Neumann | Intracellular Th | 61 | |
| John Bardi | Intracellular Th | N/A | |
| Paul Herendeen | Bausch Health Companies | 65 | |
| Andrew Plump | Takeda Pharmaceutical Co | 59 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Sven Dethlefs | Teva Pharma Industries | 55 | |
| Brendan OGrady | Teva Pharma Industries | 53 | |
| Hafrun Fridriksdottir | Teva Pharma Industries | 58 | |
| Kathleen Veit | Teva Pharma Industries | N/A | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| Giles Platford | Takeda Pharmaceutical Co | 46 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Joseph Gordon | Bausch Health Companies | 56 | |
| John Condon | Intracellular Th | N/A | |
| Gianfranco Nazzi | Teva Pharma Industries | 50 | |
| Adam Havey | Emergent Biosolutions | 53 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
Management Performance
| Return On Equity | 0.0655 | ||||
| Return On Asset | 0.0526 |
Phibro Animal Health Leadership Team
Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ramon Fuenmayor, President Region | ||
| Daniel JD, Executive Director | ||
| Larry Miller, Chief Officer | ||
| Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary | ||
| Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations | ||
| Damian Finio, Chief Officer | ||
| Mona Desai, VP Controller | ||
| Jean Filippi, Pres Region | ||
| Richard Johnson, Interim Officer | ||
| Glenn David, Chief Officer | ||
| Rob Aukerman, President Region | ||
| Anthony CPA, VP Treasurer | ||
| Jack Bendheim, Chairman of the Board and Presidentident, CEO | ||
| Daniel Bendheim, Executive Vice President Director, Corporate Strategy | ||
| Judith Weinstein, General VP | ||
| Michael Giambalvo, President Group | ||
| Lisa Escudero, Senior Vice President-Human Resources | ||
| Samson Li, President Region |
Phibro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0655 | ||||
| Return On Asset | 0.0526 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 1.38 B | ||||
| Shares Outstanding | 20.34 M | ||||
| Shares Owned By Insiders | 0.57 % | ||||
| Shares Owned By Institutions | 99.43 % | ||||
| Number Of Shares Shorted | 463.35 K | ||||
| Price To Earning | 11.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Phibro Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phibro Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phibro Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phibro Animal Health Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phibro Animal. If investors know Phibro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phibro Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.94) | Dividend Share 0.48 | Earnings Share 0.43 | Revenue Per Share 25.843 | Quarterly Revenue Growth 0.126 |
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.